ADHD Assessment And Medication Initiation Letter

Diagnosis: This letter confirms Ms. Sarah Jenkins' diagnosis of Attention Deficit Hyperactivity Disorder, predominantly inattentive presentation, following a comprehensive DIVA assessment. Her scores indicated significant impairment across multiple domains consistent with ADHD. Current Presentation: Ms. Jenkins expressed a sense of relief regarding her diagnosis, feeling that it validated many lifelong struggles. She articulated goals for improved focus at work, better organisational skills at home, and reduced emotional dysregulation. She reflected on how a late diagnosis had impacted her academic and early career progression, expressing both hope and some trepidation regarding starting medication. Relevant Psychiatric And Medical Background: Ms. Jenkins has a history of generalised anxiety disorder, well-controlled with cognitive behavioural therapy in the past. There is no family history of psychosis or tics. She denies any current substance use. Cardiovascular history is unremarkable, with no reported seizures. She is not currently pregnant and has no plans for pregnancy in the near future. Her mother has a history of hypertension, which was noted for prescribing considerations. Current Medication: Ms. Jenkins is currently taking Fluoxetine 20mg daily for anxiety, which she finds beneficial. There were no discussions regarding any uncertainty of effect or future plans for this medication. No significant interactions were identified with the proposed ADHD treatment. Treatment Discussion: We discussed both pharmacological and non-pharmacological approaches to ADHD management. Non-pharmacological strategies such as coaching, exercise, sleep structure, environmental adaptations and external organisational systems remain important components of treatment. However, medication can support attention regulation, task initiation, emotional regulation and implementation of supportive strategies. The discussion involved a detailed comparison of stimulant and non-stimulant options. Given Ms. Jenkins' primary concerns with inattention and emotional dysregulation, and her preference for a rapid onset of action, a stimulant medication was deemed the most appropriate initial choice. We discussed how stimulant medication may help with focus, task initiation, staying on track and reducing emotional reactivity, while recognising that medication has limitations and works best alongside supportive behavioural strategies and routines. After considering the options, Sarah Jenkins elected to proceed with a trial of Methylphenidate modified-release. Medication Plan: Ms. Jenkins will commence Methylphenidate modified-release at a starting dose of 18mg once daily in the morning. After one week, the dose will be increased to 36mg once daily, if well-tolerated. The prescription was issued directly to Ms. Jenkins today. Physical Monitoring: Ms. Jenkins' baseline blood pressure was 120/78 mmHg, heart rate was 72 bpm, and weight was 65 kg. Safety And Monitoring Advice: We discussed common potential side effects including appetite suppression, weight loss, headaches, palpitations, increased blood pressure and sleep disturbance. We also discussed the possibility of mood change, emotional blunting, worsening anxiety and the rare risk of stimulant-induced mania or psychosis. Advised to take medication early in the morning, ideally with breakfast. Advised to monitor sleep, appetite, mood and cardiovascular symptoms carefully. Advised to stop medication and contact me if sleeping less than 5.5 hours for two consecutive nights without feeling tired. Advised to avoid recreational drugs and to avoid combining stimulant medication with alcohol. Encouraged to nominate a trusted person who could help monitor for significant mood or behavioural change during titration. Due to concurrent use of Fluoxetine, we discussed the symptoms and risks of serotonin syndrome. Mental State: Ms. Jenkins presented as well-groomed and neatly dressed. Her behaviour was cooperative and engaged, maintaining good eye contact throughout the consultation. Speech was clear, articulate, and of normal volume and rate. Her mood was euthymic, expressing a mixture of hope and cautious optimism, and her affect was congruent. Thought form was linear and goal-directed, with no evidence of thought disorder. Thought content was primarily focused on her ADHD symptoms and treatment options, with no suicidal ideation or perceptual disturbances reported. Cognition appeared intact, and she demonstrated good insight into her condition and the need for treatment. Risk Assessment: There is no current risk to self or others. Dynamic risks include potential for medication side effects and difficulty with adherence to the titration schedule. Treatment-related risks were thoroughly discussed and understood by the patient. Protective factors include a supportive family, stable employment, and good insight into her condition. Plan: Medication and titration plan as detailed above. Resources on ADHD management and medication information will be sent to the patient via email. Monitoring arrangements will involve weekly check-ins via a secure patient portal for the first month, followed by a full review appointment. A shared care plan will be initiated with her GP for ongoing monitoring once stable on medication. Recommendations For Primary Care: We recommend that Ms. Jenkins' GP monitors her blood pressure and heart rate at her usual check-ups, especially during the initial phase of medication. Please be aware of potential medication interactions. An ECG prior to commencing treatment is not indicated given her unremarkable cardiovascular history. Follow-Up: Ms. Jenkins has a follow-up appointment scheduled for 1 November 2024 to review her progress on medication. She was advised that she could contact the clinic earlier if she experienced any significant concerns or adverse effects. Repeat Prescription Requests: If a repeat private prescription is required outside of a scheduled appointment, the following link may be used: https://secureclinicportal.com/sarahjenkins-rx Crisis Support: If you are in crisis, please contact your local urgent mental health team or attend your nearest Accident & Emergency department. You can also call the Samaritans on 116 123 or visit their website for support. For immediate medical emergencies, please call 999.